Details

Last Funding Type

Seed

Last Funding Money Raised

€14.98K

Industries

Biotechnology,Health Care,Health Diagnostics,Life Science,Medical,Therapeutics

Founded date

Sep 1, 2013

Number Of Employee

1 - 10

Operating Status

Active

LXREPAIR is a French company specialized in the development of disruptive technologies for DNA repair characterization.

LXRepair's proprietary quantitative enzymatic assays offer a unique solution to identify predictive markers of response to anti-cancer therapies based on DNA repair measurements.
DNA repair determine the response of patients to radiotherapy and chemotherapy (toxicity and resistance). LXRepair kits reveal the efficacy of DNA repair pathways from blood cells or tumor biopsy through series of fluorescent signals generated on a biochip.

By opposition to genetic approaches, the functional approach uncovers the real effectiveness of repair activities; multiplexing provides multiple information across the entire DNA repair network. These advantages make LXRepair tests more relevant and informative than other repair assays to identify DNA repair defects responsible for treatment failures.


Another major objective of LXRepair is to achieve the CE-IVD marking of its first kit in 2020 to predict the occurrence of radiotoxicity events.

LXRepair is supported by Canceropole CLARA and Bpi.

LXRepair innovative platform offers powerful tools for R&D labs investigating DNA repair mechanisms in Drug Development and in ageing sciences.
e company and start-up.

LXRepair has raised funding in Sept 2017 with KREAXI, CEA-Investment, XPAND INVESTMENT Ltd of the KIS Group, Grenoble Angels, Savoie Mont-Blanc Angels, Gentiane Participation and individual investors.
The funding will enable LXRepair to complete the prospective clinical studies initiated to identify:
• Blood biomarkers of radiotoxicity (breast and prostate cancer)
• Tumor biomarkers of radio-chemo resistance (head and neck cancer)